Although there were initial concerns for an association between lymphomas and tumor necrosis factor-α inhibitors, recent study of long-term adverse events of adalimumab in a large group of patients with Crohn’s disease found the lymphoma rate for patients on adalimumab was below the estimated background rate.7 Here, TNF is linked to lymphoma.